
Please try another search
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Arcus Biosciences (RCUS) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Arcus Biosciences is a member of our Medical group, which includes 899 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 8.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, RCUS has returned 23.96% so far this year. Meanwhile, the Medical sector has returned an average of -21.21% on a year-to-date basis. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has lost an average of 19.04% so far this year, meaning that RCUS is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to RCUS as it looks to continue its solid performance.
The fortune of Nvidia (NASDAQ:NVDA) is closely tied to Big Tech hyperscalers. Although the AI/GPU designer didn’t name its largest clients in the latest 10-K filing on Wednesday,...
In a market fraught with uncertainty, investors often seek refuge in defensive-minded stocks that offer stability and resilience. Two such stalwarts, Johnson & Johnson and...
The United States is the largest exporter of liquefied natural gas (LNG), having surpassed Australia and Qatar in 2023. The United States exports an estimated 12.5 billion cubic...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.